The role of cutaneous T-cell attracting chemokine in the development of different phenotypes of atopic dermatitis in children

Authors

  • V.O. Dytiatkovsky Dnipro State Medical University , V. Vernadsky str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0002-8508-5562
  • O.Є. Abaturov Dnipro State Medical University , V. Vernadsky str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-6291-5386
  • N.V. Naumenko Allergological Center of the Municipal Communal Enterprise "Clinical Hospital of Ambulance" of the Dnipro City Council, V. Antonovycha str., 65, Dnipro, 49006, Ukraine
  • O.O. Alifirenko Allergological Center of the Municipal Communal Enterprise "Clinical Hospital of Ambulance" of the Dnipro City Council, V. Antonovycha str., 65, Dnipro, 49006, Ukraine
  • I.A. Filatova Allergological Center of the Municipal Communal Enterprise "Clinical Hospital of Ambulance" of the Dnipro City Council, V. Antonovycha str., 65, Dnipro, 49006, Ukraine
  • S.M. Taran Allergological Center of the Municipal Communal Enterprise "Clinical Hospital of Ambulance" of the Dnipro City Council, V. Antonovycha str., 65, Dnipro, 49006, Ukraine

DOI:

https://doi.org/10.26641/2307-0404.2021.3.241933

Keywords:

atopic dermatitis, children, phenotypes, risk, cutaneous T-cell attracting chemokine

Abstract

The goal of this study was to detect the risk of developing different atopic dermatitis (AD) phenotypes in children (isolated or combined with other comorbid atopic diseases (AtD)) depending on serum concentrations of cutaneous T-cell attracting chemokine (CTACK)/CCL27. The main group comprised 39 children aged 3 to 18 years old suffering from different AD phenotypes – isolated (18 patients) and combined with comorbid AtD – AR/ARC and/or bronchial asthma (21 patients). The control group comprised 47 children aged 3 to 18 years old, suffering from diseases of the gastrointestinal tract (GIT). Serum CTACK/CCL 27 concentrations were detected in all children. In the full main group, the average level of CTACK/CCL27 was significantly higher compared to the patients of the control group: 4403.6 pg/ml (95% CI: 3726.2; 5148.7, p<0.001) and 3495.9 pg/ml (95% CI: 3197.8; 4186.8, p<0.001), respectively. Mean serum CTACK/CCL27 levels in patients of the main group with different AD phenotypes were higher than those in the full main group: with isolated AD – 4549.4 pg/ml (LQ; HQ: 3923.5; 5175.2, p<0.05), with AD associated with other AtD – 5116.6 pg/ml (LQ, HQ: 4062.8; 6170.5, p<0.05). In phenotypes of overall and isolated AD, the cut-off value of serum CTACK/ CCL27 is 3586.5 pg/ml (76.9% and 77.8%, respectively, and 38.3% in the control group). The risk of development at this concentration is 5.37 (95% CI: 2.05; 14.07, p<0.001) for the total AD phenotype and 5.64 (95% 1.56; 20.32, p<0.05) for the isolated AD phenotype. In AD phenotype combined with comorbid AtD, the cut-off value of serum CTACK/CCL27 is 4308.8 pg/ml (66.7% of the main and 21.3% in the control group). The risk of developing this AD phenotype at this concentration is 7.40 (95% CI: 2.30; 23.76, p<0.001). Serum CTACK/CCL27 levels are the reliable biomarker of the risk for developing different AD phenotypes in children. In the serum level of CTACK/CCL27=3658.5 pg/ml, the significant risk of developing total AD phenotype is 5.37, and isolated – AD=5.64. In the serum concentration of CTACK/CCL27=4308.8 pg/ml, the significant risk of developing AD phenotype combined with comorbid AtD is 7.40.

References

Antomonov MY. [Mathematical processing and analysis of medical and biologic data]. 2-d ed. Kyiv: IIC «Medinform»; 2018. p. 579. Russian.

Dytiatkovskyi VO, Abaturov OE, Naumenko NV, Pinayeva NL, Alifirenko OO, Taran SM, et al. Associations of the novel chemokine-based diagnostic bio¬marker panel with different phenotypes of atopic dermatitis in children. Paediatrics. Eastern Europe. 2021;9(1):20-31. doi: https://doi.org/10.34883/PI.2021.9.1.002

Belgrave DCM, Simpson A, Buchan IE, et al. Atopic dermatitis and respiratory allergy: what is the link. Curr Derm. 2015;221-7. doi: https://doi.org/10.1007/s13671-015-0121-6

Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453-60. doi: https://doi.org/10.1097/ACI.0000000000000198

Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Coun¬cil. J Allergy Clin Immunol. 2021 Jan 28:S0091-6749(21)00096-8. doi: https://doi.org/10.1016/j.jaci.2021.01.013

Clausen ML, Kezic S, Olesen CM, Agner T. Cytokine concentration across the stratum corneum in atopic dermatitis and healthy controls. Sci Rep. 2020;10(1):21895. doi: https://doi.org/10.1038/s41598-020-78943-6

Roekevisch E, Szegedi K, Hack DP, Schram ME, Res PCJM, Bos JD, et al. Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1545-54. doi: https://doi.org/10.1111/jdv.16164

Hulshof L, Overbeek SA, Wyllie AL, Chu MLJN, Bogaert D, de Jager W, et al. Clinical Study Group. Exploring immune development in infants with moderate to severe atopic dermatitis. Front Immunol. 2018 Mar;9:630. doi: https://doi.org/10.3389/fimmu.2018.00630

Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: https://doi.org/10.1016/j.jaad.2013.10.010

Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. Clin Exp Allergy. 2006 Mar;36(3):346-51. doi: https://doi.org/10.1111/j.1365-2222.2006.02430.x

Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013 Apr;70(1):3-11. doi: https://doi.org/10.1016/j.jdermsci.2013.02.001

Kim JE, Kim JS, Cho DH, Park HJ. Molecular mechanisms of cutaneous inflammatory disorder: atopic dermatitis. Int J Mol Sci. 2016 Jul 30;17(8):1234. doi: https://doi.org/10.3390/ijms17081234

Amat F, Soria A, Tallon P, Bourgoin-Heck M, Lambert N, Deschildre A, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: an overview. Clin Exp Allergy. 2018 Aug;48(8):919-34. doi: https://doi.org/10.1111/cea.13156

Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012 Dec;130(6):1344-54. doi: https://doi.org/10.1016/j.jaci.2012.07.012

Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol. 2008 Nov;19(7):605-13. doi: https://doi.org/10.1111/j.1399-3038.2007.00692.x

Machura E, Rusek-Zychma M, Jachimowicz M, Wrzask M, Mazur B, Kasperska-Zajac A. Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. Pediatr Allergy Immunol. 2012 May;23(3):278-84. doi: https://doi.org/10.1111/j.1399-3038.2011.01225.x

Kryuchko TO, Bubyr LM, Nesina IM, Tkachenko OY, Izmailova OV, Poda OA et al. Ways of optimizing the diagnostics of food allergies in children based on the clinical and immunological criteria. Wiad Lek. 2020;73(10):2255-60. PMID: 33310959. doi: https://doi.org/10.36740/WLek202010129

Downloads

Published

2021-09-30

How to Cite

1.
Dytiatkovsky V, Abaturov O, Naumenko N, Alifirenko O, Filatova I, Taran S. The role of cutaneous T-cell attracting chemokine in the development of different phenotypes of atopic dermatitis in children. Med. perspekt. [Internet]. 2021Sep.30 [cited 2024Nov.20];26(3):39-46. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/241933

Issue

Vol. 26 No. 3 (2021)

Section

CLINICAL MEDICINE

License

Copyright (c) 2021 Medicni perspektivi (Medical perspectives)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.

Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.